28-Mar-2025
Major Moves by Shareholder: Adverum Biotechnologies Stock in Focus
TipRanks (Thu, 27-Mar 10:02 PM ET)
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
Globe Newswire (Mon, 3-Mar 4:01 PM ET)
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 28-Feb 4:00 PM ET)
Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference
Globe Newswire (Tue, 25-Feb 7:00 AM ET)
Globe Newswire (Wed, 5-Feb 4:05 PM ET)
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Adverum Biotechnologies trades on the NASDAQ stock market under the symbol ADVM.
As of March 28, 2025, ADVM stock price declined to $4.61 with 127,766 million shares trading.
ADVM has a beta of 1.03, meaning it tends to be more sensitive to market movements. ADVM has a correlation of 0.04 to the broad based SPY ETF.
ADVM has a market cap of $95.89 million. This is considered a Micro Cap stock.
Last quarter Adverum Biotechnologies reported $1,000 in Revenue and -$1.30 earnings per share. This fell short of revenue expectation by $-99,000 and exceeded earnings estimates by $.01.
In the last 3 years, ADVM traded as high as $29.70 and as low as $3.52.
The top ETF exchange traded funds that ADVM belongs to (by Net Assets): IWM, VTI, VXF, IWN, VTWO.
ADVM has underperformed the market in the last year with a return of -67.4%, while SPY returned +7.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ADVM shares. However, ADVM has outperformed the market in the last 3 month and 2 week periods, returning -4.0% and 0.0%, while SPY returned -6.3% and -1.0%, respectively. This indicates ADVM has been having a stronger performance recently.
ADVM support price is $4.64 and resistance is $5.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADVM shares will trade within this expected range on the day.